When was Converge founded?

Converge was founded in 2024 and raised its 1st funding round within a year of its incorporation.

Where is Converge located?

Converge is headquartered in Wilmington, United States.

Who is the current CEO of Converge?

Dov Gertz of Converge. They have also founded 1 company.

How many employees does Converge have?

As of Jun 30, 2026, the latest employee count at Converge is 52.

Is Converge a funded company?

Converge is a funded company, having raised a total of $30.5M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 20, 2024.

When was the latest funding round of Converge?

Converge's latest funding was a $***** Grant (prize money) round on Jun 01, 2026, with participation from 1 investor.

Where does Converge rank among its competitors?

Converge ranks 12th amongst 79 active competitors, of which 42 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Converge, which secured $2.5M in Jun, 2026.

Who are the top competitors of Converge?

Converge's top competitors include Nimbus Therapeutics, Generate Biomedicines and Cradle. Among them, Converge secured the most recent funding round in June, 2026.

Converge - 2026 Company Profile, Team, Funding & Competitors

Converge is a series A company based in Wilmington (United States), founded in 2024 by Dov Gertz and Oded Kalev. It operates as a Developer of GenAI computational tools for drug discovery and manufacturing. Converge has raised $30.5M in funding from Bessemer Venture Partners and TLV Partners. The company has 79 active competitors, including 42 funded and 5 that have exited. Its top competitors include companies like Nimbus Therapeutics, Generate Biomedicines and Cradle.

Company Details

Developer of GenAI computational tools for drug discovery and manufacturing. The company offers a bio-LLM library with foundation models across biological languages. These models are enhanced with curated data and fine-tuned on task-specific datasets. The platform is deployed through an application layer focused on prediction, explainability, and generation. It provides AI-driven antibody discovery and optimization, protein yield maximization, and cellular response prediction. The platform ensures data privacy and security, offering complete control and fully managed infrastructure.

Key Metrics

Founded Year

2024

Location

Wilmington, United States

Stage

Series A

Total Funding

$30.5M in 3 rounds

Latest Funding Round

Grant (prize money), Jun 01, 2026, $*****

Investors

Bessemer Venture Partners & 4 more

Ranked

12^th among 79 active competitors

Employee Count

52 as on Jun 30, 2026

Similar Companies

OpenEvidence & 2418 more

View Converge's full profile

Converge has raised a total funding of $30.5M over 3 rounds. Its first funding round was on Nov 20, 2024. Its latest funding round was a Grant (prize money) round on Jun 01, 2026 for $*****. 1 investor participated in its latest round. Converge has 5 institutional investors.

Here is the list of recent funding rounds of Converge:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2026	1941173	Grant (prize money)	3669402	8620739	7852293	1405870
Sep 24, 2025	9863887	Series A	4935830	5682203	5753622	TLV Partners & 2 more
Nov 20, 2024	2152646	Seed	1524715	8603780	TLV Partners	2540587

Access funding benchmarks and valuations. Sign up today!

View details of Converge's funding rounds and investors

The founders of Converge are Dov Gertz and Oded Kalev. Dov Gertz is the CEO of Converge.

Here are the details of Converge's key team members:

Dov Gertz: Co-Founder & CEO of Converge.
Contact Info: 1 email address
Oded Kalev: Co Founder & CTO of Converge.
Contact Info: 1 email address

View details of Converge's Founder profiles and Board Members

Converge's employee count trend

Converge has 52 employees as of Jun 26. Here is Converge's employee count trend over the years:

Uncover Converge's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Converge include Nimbus Therapeutics, Generate Biomedicines and Cradle. Here is the list of Top 10 competitors of Converge, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	NVentures, March Capital & 14 others	66/100
3rd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, IVP & 7 others	64/100
4th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Lux Capital, Amazon & 3 others	64/100
5th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Insight Partners, Altimeter Capital & 6 others	64/100
6th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	64/100
7th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, Foresite Capital & 22 others	62/100
8th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	61/100
9th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Versant Ventures & 21 others	61/100
10th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, Innovate UK & 11 others	59/100
12th	Converge 2024, Wilmington (United States), Series A	Developer of GenAI computational tools for drug discovery and manufacturing	$30.5M	Vintage Investment Partners, TLV Partners ... & 3 others	56/100